The Food and Drug Administration approved Gwyn Lo, a once-weekly contraceptive patch made by Viatris, on July 29 [1]. The patch delivers 220 micrograms of norelgestromin and 20 micrograms of ethinyl estradiol a day, is applied once a week rather than swallowed daily, and is expected to reach the market later this year [1].
The approval carries a restriction that appears in the company's announcement once, down in the safety block. The release states that Gwyn Lo is contraindicated in women with a BMI of 30 kg/m2 or above, and the approval itself is limited to women with a BMI below 30 [1]. A contraindication is not a caution, a dosing note or a discussion to have with a clinician. It means the drug should not be used.
The National Institute of Diabetes and Digestive and Kidney Diseases puts obesity prevalence, defined as a BMI of 30 or above, at 41.9 percent among US women, drawing on the 2017-2018 National Health and Nutrition Examination Survey [2]. Roughly four in ten American adult women therefore sit outside the population this patch was approved for, on the day it was approved.
The release does not say why. It offers no explanation for the BMI limit, no efficacy or safety data broken out by body mass, and no indication of whether the threshold reflects reduced effectiveness, an elevated cardiovascular risk, or simply the enrolment criteria of the trial that supported the application. The full prescribing information will carry more than the announcement does, and anyone writing about this product should read it before repeating the company's framing.
On effectiveness the release reports a Pearl Index of 4.14, with a 95 percent confidence interval of 2.77 to 5.95, among women aged 18 to 35 in the Phase 3 Luminous study [1]. A Pearl Index of 4.14 means roughly four pregnancies for every 100 women using the method for a year.
That number needs a scale beside it. The Guttmacher Institute puts first-year failure at 7 percent for the combined pill in typical use and 7 percent for the contraceptive patch in typical use, against under 1 percent for each when used perfectly [3]. For the hormonal IUD, the copper IUD and the contraceptive implant, Guttmacher reports under 1 percent in both typical and perfect use, and describes the implant and the IUD as the most effective reversible methods available [3].
Two things follow. Gwyn Lo's trial figure sits below the typical-use failure rate for the pills and patches already on the market and above their perfect-use figure, which is roughly what a supervised trial would be expected to produce. Measured against an IUD or an implant it is several times worse. A person choosing between a weekly patch and a device that lasts years is choosing between about four pregnancies per 100 women a year and fewer than one.
One caveat belongs on that comparison. A Pearl Index calculated over trial cycles and a 12-month typical-use failure rate are related but not identical measures, and Guttmacher's figures describe real-world use while the 4.14 describes trial conditions [3]. The direction of the gap between this patch and an implant is not in question. The precise ratio is not something these two sources can settle between them.
The adhesion data is the release's strongest number and it holds up. Of 39,790 transdermal systems applied over the year-long trial, 1.3 percent fully detached [1], which works out to roughly 517 patches. For a delivery method whose historical weakness is falling off in the shower or the heat, that is a real result and it deserves to be reported as one.
What the announcement leads with differs from what the label restricts. Viatris chief research and development officer Philippe Martin is quoted describing "a discreet option for women seeking a reversible, non-invasive, once-weekly contraception patch with a low dose of estrogen" [1]. Discreet, non-invasive and low-dose are all accurate descriptions. The sentence that determines whether a given woman can use the product at all is the contraindication, and it is not in the quote.
The release carries a second contraindication that predates this product and applies across combined hormonal contraceptives: Gwyn Lo is contraindicated in women who smoke and are over 35, because of an increased risk of serious cardiovascular events [1].
A new contraceptive method is good news, and it should be recorded as good news. More women get an option that does not depend on remembering a pill at the same hour every day, and the detachment figure suggests it will stay where it is put. The good news has an edge on it the announcement does not draw. The label excludes a share of American women large enough that the first question at the appointment will be a number on a scale, and the effectiveness figure lands nearer a pill than an IUD. Someone deciding between methods is owed both halves of that.
